Risk of Market Changes and Loss of Technological Advantages Due to Innovation
First written in FY2016. 3 of 6 entries say "Restated". Latest entry: FY2026.
Transgenic Group moved to the "Worse" side of this theme in 2018, 4 years before the typical company in this theme (2022).
The whole theme swung hardest in 2022: 5 of 10 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If technological innovation causes rapid changes in the market and the Group loses its technological advantages over competitors, this could have a material impact on the Group's performance.」
The Company reconfirms the risk of market changes resulting from technological innovation and the loss of competitive advantage. - FY2020RestatedAnnual report
「However, if technological innovation causes rapid changes in the market and the Group loses its technological advantages over competitors, this could have a material impact on the Group's performance.」
The Company reconfirms the risk of market changes resulting from technological innovation and the loss of competitive advantage as a key business-environment risk. - FY2019MaterialisedAnnual report
「Orders from academia and public institutions for the production and sale of genetically modified mice declined following the emergence of technological innovations that enabled academic researchers to produce genetically modified mice themselves.」
Because orders declined as genetically modified mouse production technologies became more widespread and the earnings initially expected from part of the CRO business could no longer be anticipated, the Company recorded an impairment loss of ¥29.777 million. - FY2018-Q3MaterialisedAnnual report
「In this business, amid a trend toward reduced research and development budgets among academia and other major customers and the spread of technologies for producing genetically modified mice, the opening order backlog had declined year on year. In addition, orders received during the period, including contracted mouse production, remained sluggish, resulting in year-on-year decreases in net sales and operating income.」
The Company identifies reduced research and development budgets and the spread of genetically modified mouse production technologies as factors behind sluggish orders and lower revenue and profit, with changes in the technological and market environment reflected in business performance. - FY2017RestatedAnnual report
「Market changes resulting from technological innovation and the loss of technological advantages over competitors could have a material impact on the performance of the Group.」
The Company continues to identify technological innovation and the loss of competitive advantage as risks. - FY2016First statedAnnual report
「Market changes resulting from technological innovation and the loss of technological advantages over competitors could have a material impact on the performance of the Group.」
Against a backdrop of rapid technological development in the biotechnology industry, the Company identifies the loss of competitive advantage as a risk.